• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Janssen R&D Ireland - Articles and news items

Janssen Pharmaceuticals Logo

Janssen demonstrates continued commitment to combating Hepatitis C in European patients with data presented at Viral Hepatitis Congress

Industry news / 10 October 2014 / Janssen

New data demonstrates efficacy and safety of OLYSIO® (simeprevir) in broader patient populations…

ViiV Healthcare Logo

ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

Industry news / 12 June 2014 / GlaxoSmithKline

Agreement is ViiV Healthcare’s first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine…

Janssen Pharmaceuticals Logo

Simeprevir administered once daily demonstrates sustained virologic response in genotype 1 chronic hepatitis C patients

Industry news / 11 November 2013 / Janssen Therapeutics EMEA

HCV is a major problem in the EMEA region, where an estimated 15 million people are living with the disease…

Janssen Pharmaceuticals Logo

Simeprevir administered once daily as part of combination therapy demonstrates sustained virologic response in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C adult patients

Industry news / 2 November 2013 / Janssen R&D Ireland

“The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option…”

Janssen Pharmaceuticals Logo

European Commission approves PREZISTA® (darunavir) 800mg tablet once a day

Industry news, News / 16 January 2013 / prnewswire.co.uk

The European Commission has approved a new PREZISTA® (darunavir) 800mg tablet…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +